Recent genetic evidence indicates that neuregulin 1 (NRG1) and its receptor erbB4 may be susceptibility genes in schizophrenia, but their function in CNS synaptic transmission and circuitry is not well understood. In this issue of Neuron, studies from Li et al. and Woo et al. show that NRG1 and erbB4 regulate transmission at brain glutamate and GABA synapses. These findings raise the possibility of synaptic defects in schizophrenia.
Recent genetic evidence indicates that neuregulin 1 (NRG1) and its receptor erbB4 may be susceptibility genes in schizophrenia, but their function in CNS synaptic transmission and circuitry is not well understood. In this issue of Neuron, studies from Li et al. and Woo et al. show that NRG1 and erbB4 regulate transmission at brain glutamate and GABA synapses. These findings raise the possibility of synaptic defects in schizophrenia.
Two papers in this issue of Neuron describe effects of erbB4 activation on synaptic transmission in the CNS. Li and colleagues report that overexpression of erbB4 enhances AMPA receptor-mediated EPSCs in rodent CA1 hippocampal pyramidal cells evoked by stimulation of Schaffer collaterals from CA3. Woo and colleagues show that NRG1 enhances GABA release from interneurons in the prefrontal cortex. Downregulation of NRG1 or erbB4 have the opposite effects. Both groups point out the relevance of their results toward a molecular understanding of schizophrenia, and this will be discussed below. First, the promise these studies hold for future molecular manipulation of synaptic efficacy and for our understanding of neural circuits should be emphasized. Li et al. (2007) demonstrated erbB4-activated increases in AMPAR-mediated synaptic currents by recording simultaneously from an erbB4-transfected neuron in CA1 and a nearby untransfected control neuron. Transfection with erbB4 also increased the size of CA1 dendritic spines but not their number per unit length along the dendritic shaft. Taken together, these data imply that activation of erbB4 increases the number of AMPARs per spine head, perhaps by increasing the packing density in the postsynaptic membrane. Transfection with erbB4 did not increase NMDA receptor-mediated currents, but a reduction of erbB4 levels with RNAi reduced NMDA receptor as well as AMPA receptor-mediated currents. In addition, APV, an NMDA receptor antagonist, blocked the effect of erbB4 on AMPARs, implying a role for NMDAR activation in NRG1 regulation of AMPA receptor number. Interestingly, erbB4 knockdown (with erbB RNAi or with a kinase-dead form of erbB4 [erbB4-KD] reduced long-term potentiation (LTP) in CA1 as well as single EPSCs (see Kwon et al. [2005] ). Woo et al. (2007) found that erbB4 receptors are concentrated in GABAergic nerve terminals in brain slices prepared from the prefrontal cortex. NRG1 added to cortical slices or to synaptosomes prepared from homogenates of prefrontal cortex produced a 2-to 4-fold increase in the amount of GABA released into the medium during a 10 min ''pulse'' of 20 mM K + . No effect of NRG on evoked GABA release was detected in erbB4 knockout mice that survived beyond E10 by selective expression of erbB4 in the heart (erbB4 À/À ht). Paired-pulse IPSC ratios were reduced, suggesting a NRG1-induced increase in fractional release from the readily releasable GABA vesicle pool.
Both Li et al. (2007) and Woo et al. (2007) present evidence for regulation by endogenous NRG1. ErbB4 RNAi dramatically reduced AMPA-mediated EPSCs in the hippocampus in the absence of added NRG1, and erbB4 antagonists reduced depolarizationevoked GABA release in slices from the prefrontal cortex. In another recent study, evidence for endogenous NRG1 action was found in studies of nicotinic ACh receptors on GABAergic interneurons in hippocampal slices (Chang and Fischbach, 2006) . Concentration matters. Timing matters too. It will be important to distinguish between rapid effects of erbB4 kinase activation and longer-term effects that may depend on changes in gene expression. Where is endogenous NRG1 located? One might assume that NRG1 is released from presynaptic boutons and that it activates erbB4 receptors in the postsynaptic membrane, but variations on that theme are certainly possible. For example, the extracellular domains of NRG1 or of erbB4 may be cleaved and bound in the extracellular matrix, or they may diffuse some distance from the synapse. Regulation of AMPA receptor density and of GABA release might be cell-autonomous phenomena whereby NRG1 and erbB4 might be synthesized and act within the same cell.
A key role for synaptic and/or impulse activity was found in both studies. In the hippocampus, the amount of erbB4 exposed on the surface of dendritic spines, the level of erbB4 activation, and augmentation of AMPA currents were all reduced in the presence of picrotoxin, tetrodotoxin (TTX), or elevated Mg. These striking findings were documented by immunoprecipitation, cell fractionation, and, at the level of individual spines, by twophoton laser-scanning microscopy. It remains to be determined if neuronal activity enhances the phosphorylation of erbB4 by promoting its insertion into the surface membrane, binding of NRG1, or dimerization of unliganded erbB receptors. Li et al. (2007) suggest a positive-feedback loop in which synaptic activity upregulates NRG1 signaling and this, in turn, enhances the efficacy of glutamatergic synaptic transmission leading to further activation of erbB4. A ''switch'' of this sort might play a key role during critical periods of synapse formation or stabilization. Likewise, Woo et al. (2007) found that the effect of NRG1 on GABAergic nerve terminals was dependent on activity. No effect of NRG1 was observed in unstimulated preparations or on spontaneous miniature IPSPs. It will be important to explore the biochemical pathways by which ''activity,'' in the form of brief synaptic events or a steady depolarization, influences NRG1 function in central synapses.
Taken together, these papers showcase the power of modern molecular genetics for manipulation of cells, synapses, and neural circuits. The ability to shift the concentrations of key signaling molecules in a graded fashion adds an element of control that was unimaginable a few years ago. One might stop at elegant molecular dissections of the role of neuregulin and erbB4 in synaptic transmission, but there is an irresistible urge to place these results in the context of schizophrenia. This is understandable considering the recent discoveries of schizophrenia-risk haplotypes associated with the NRG1 gene (Stefansson et al., 2002; Harrison and Law, 2006) and the erbB4 gene (Silberberg et al., 2006) . In addition, increasing evidence implicates glutamate and GABA hypofunction in schizophrenia (Lewis and Moghaddam, 2006) . In one speculative scenario, the schizophrenia risk haplotypes might result in NRG1 hypofunction, leading to a decrease in the efficacy of glutamate and GABA-mediated synaptic transmission in the prefrontal cortex, which could produce desynchronized firing of pyramidal neurons, the loss of gamma waves recorded from the brain surface, and behavioral deficits in working memory, an important hallmark of schizophrenia. Such oversimplified schemes have their uses, in that they allow one to think about disorganized thoughts in an organized way, and illustrate the paths one might hope to follow in a bottom-up approach to understanding complex mental and behavioral phenomena.
The studies by Li et al. (2007) and Woo et al. (2007) provide a platform for future work by raising questions that should be addressed. For example not all GABAergic interneurons in the prefrontal cortex contribute to pyramidal neuron synchronization. Prior work suggests that the subset of interneurons that express parvalbumin and that terminate on or near the axon hillock of pyramidal neurons are particularly important in pyramidal cell synchronization and in working memory . It is interesting that Woo et al. (2007) found that erbB4 is present in only a subset of GABAergic nerve terminals in the prefrontal cortex, and thus it will be important to determine if these are terminals of parvalbumin containing interneurons. Likewise, other neurotransmitters are certainly involved in the full complex of symptoms that comprise schizophrenia. Neuroleptic drugs that relieve psychotic and other positive symptoms of schizophrenia are dopamine-receptor antagonists, and dopamine is a prime suspect in the striatum and prefrontal cortex. Schizophrenic patients often ''self-medicate'' by smoking, so nicotinic ACh receptors are also suspect. Long-term exposure to NRG1 increases the number of a-7 nicotinic AChRs on GABAergic interneurons in the hippocampus (Liu et al., 2001 ), but short-term exposure, on a scale of seconds to minutes, decreases a-7 currents and EPSCs (Chang and Fischbach, 2006) . Thus, the effect on excitatory synaptic drive and hence the release of GABA may be a matter of timing-an issue that will clearly not be straightforward to dissect in the case of multiple endogenous neuromodulators.
While appreciating the elegant studies in central synapses, it is worth pointing out the important role that work in peripheral synapses and axons has played in paving the way for discoveries in the CNS. The neurotrophins provide the prime example. Of particular relevance here is the fact that two of the founding members of the NRG1 family were initially identified based on assays of AChR synthesis in skeletal myotubes and proliferation of peripheral Schwann cells, respectively. This is not a one-way street. As shown by the papers in this issue, synaptic activity modulates the activation of erbB4 at central synapses. Thus, one might ask whether synaptic or impulse activity is important for the localization and activation of erbB4 at the neuromuscular junction or along peripheral axons.
The effects of NRG1 are not limited to neurotransmission and ligand-gated receptors. Several key developmental processes including the proliferation, migration, and fate determination of neuronal and glial precursors are influenced by NRG1 (Buonanno and Fischbach, 2001; Falls, 2003) . Any or all of these processes may contribute to the formation and efficacy of synapses in critical areas of the brain. Furthermore, the emphasis here has been on NRG1, but other proteins that influence early development or synaptic plasticity in the adult have been implicated as risk factors for schizophrenia. BDNF heads this list, with significant effects on GABA synthesis and release , and DISC1 encodes a protein that interacts with PDEB4, microtubule-based motor complexes, and other proteins that are likely regulators of synaptic function (Porteous et al., 2006) . In summary, the studies by Li et al. (2007) and Woo et al. (2007) take us one step closer to understanding the synaptic transmission and local circuit deficits in schizophrenia, but exactly how and to what extent these defects may contribute to the characteristic disease symptoms and etiology is a challenge for future research.
Astrocytes undergo elevations in intracellular calcium following activation of metabotropic receptors, which may trigger glutamate secretion and excitation of surrounding neurons. In this issue of Neuron, Fiacco et al. use transgenic mice that express a foreign G q -coupled receptor in astrocytes to show that selective stimulation of astrocytes is not sufficient to induce the release of glutamate.
Calcium transients are as prevalent in astrocytes as action potentials in neurons. They are induced by activation of metabotropic receptors following transmitter release from nerve terminals and can propagate as waves through processes and among neighboring astrocytes via ATP release. based excitability is a fundamental aspect of astrocyte biology in situ. While such signaling could initiate morphological changes or alter gene expression, events more or less constrained to astrocytes, the intimate relationship between astrocytes and neurons has raised the possibility that such events could also influence neuronal activity on a rapid timescale.
